<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diminishing Returns of Prolonged PD-1 Exposure Versus Rising Late Toxicity and Cost - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-32</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-32</p>
                <p><strong>Name:</strong> Diminishing Returns of Prolonged PD-1 Exposure Versus Rising Late Toxicity and Cost</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.</p>
                <p><strong>Description:</strong> Most clinical benefit of anti–PD-1 in advanced melanoma accrues in the first 6–12 months for responders, while continued exposure beyond 12–24 months yields diminishing incremental efficacy but increases cumulative risks of late/delayed irAEs and substantial financial toxicity. Rational caps or early discontinuation when disease is immunologically quiescent maximize net clinical value.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>DANTE will demonstrate non-inferior PFS at 24 months from start among biomarker-selected early-stoppers versus continuers, with lower grade ≥3 irAEs and improved cost-effectiveness.</li>
                <li>STOP-GAP will show similar OS between stop-at-maximal-response and 2-year continuation, with fewer late irAEs in the stop arm.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>QoL and work productivity gains from earlier stopping will exceed any modest loss in PFS in most responders, yielding superior net health utility.</li>
                <li>Health-economic models will favor PET/ctDNA-guided early-stop strategies across diverse healthcare systems.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If prolonged exposure (>24 months) substantially increases cure fraction beyond biomarker-selected early stops, the diminishing returns premise would be undermined.</li>
                <li>If cost-effectiveness analyses favor continuation due to reduced retreatment/rescue costs, the economic corollary would be weakened.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Precise individual-level toxicity risk stratification by duration is not defined; heterogeneity across centers and dosing. <a href="../results/extraction-result-80.html#e80.0" class="evidence-link">[e80.0]</a> <a href="../results/extraction-result-87.html#e87.10" class="evidence-link">[e87.10]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>